- Home
- MREO vs IMUX Comparison
MREO vs IMUX Comparison
Compare MREO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | IMUX |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | 66 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 152.6M |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MREO | IMUX |
|---|---|---|
| Price | $0.33 | $1.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $1.50 | ★ $4.80 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $6,000.20 | N/A |
| Revenue Next Year | $34.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.51 |
| 52 Week High | $2.94 | $1.51 |
Technical Indicators
Market Signals| Indicator | MREO | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 53.23 |
| Support Level | $0.32 | $1.05 |
| Resistance Level | $0.42 | $1.35 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 29.29 | 53.13 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.